GlassScriptPhysician profile
Javier Zelaya
NPI 1760494355
$5,149.60
in general payments reported to CMS, 2019-2025
23 companies · $14.04 in 2025
The $14.04 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,752 · 2020: $386 · 2021: $261 · 2022: $283 · 2023: $222 · 2024: $231 · 2025: $14.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $365 · Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $364.96 |
| Food and Beverage | $101.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,440.01 | 2019-2020 | |
| Janssen Biotech, INC. | $504.54 | 2019-2024 | Tremfya |
| Leo Pharma INC. | $476.85 | 2019-2021 | |
| Abbvie INC. | $357.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $354.02 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2019 | |
| Galderma Laboratories, L.P. | $269.37 | 2019-2023 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $207.04 | 2019-2020 | |
| Almirall LLC | $198.92 | 2019-2024 | Seysara |
| Mayne Pharma Commercial LLC | $144.84 | 2019 | |
| Celgene Corporation | $123.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $122.43 | 2019 | |
| Epi Health, LLC | $120.18 | 2019-2020 | |
| Lilly USA, LLC | $94.49 | 2019-2024 | Ebglyss, Taltz |
| Genzyme Corporation | $88.88 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $63.48 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.47 | 2019 | |
| Genentech USA, INC. | $55.46 | 2019 | |
| Journey Medical Corporation | $41.38 | 2019 | |
| Ucb, INC. | $33.28 | 2019-2020 | |
| Dermavant Sciences, INC. | $17.20 | 2024 | Vtama |
| Amgen INC. | $14.04 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Zelaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.